Eculizumab in kidney diseases

• Κύριοι συγγραφείς: Fatemeh Pour- (Συγγραφέας), Sara Assadiasl (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Society of Diabetic Nephropathy Prevention, 2024-01-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...